Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017

[1]  T. Conroy,et al.  Metastatic Pancreatic Cancer: ASCO Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Petricoin,et al.  Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. , 2020, The Lancet. Oncology.

[3]  A. Aguirre.  Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer , 2019, Clinical Cancer Research.

[4]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[5]  J. Ross,et al.  Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. , 2019, Gastroenterology.

[6]  Edward S. Kim,et al.  The current state of molecular testing in the treatment of patients with solid tumors, 2019 , 2019, CA: a cancer journal for clinicians.

[7]  David Bonekamp,et al.  NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. , 2018, Cancer discovery.

[8]  Nicholas D. Camarda,et al.  Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. , 2018, Cancer discovery.

[9]  E. Petricoin,et al.  Precision medicine for pancreatic cancer patients:preliminary results from the know your tumor program. , 2018 .

[10]  A. Biankin,et al.  Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. , 2018, JCO precision oncology.

[11]  E. Benarroch,et al.  DNA damage response , 2018, Neurology.

[12]  R. Moffitt,et al.  Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial , 2017, Clinical Cancer Research.

[13]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[14]  N. Schultz,et al.  Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype , 2017, Clinical Cancer Research.

[15]  J. Lacy,et al.  Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  Gun Ho Jang,et al.  A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns , 2016, Nature.

[17]  T. Kipps,et al.  ATM Mutations in Cancer: Therapeutic Implications , 2016, Molecular Cancer Therapeutics.

[18]  C. Iacobuzio-Donahue,et al.  Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy , 2016, Expert opinion on therapeutic targets.

[19]  J. Potash,et al.  Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. , 2016, Cancer discovery.

[20]  David M. Thomas,et al.  Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial , 2015, Clinical Cancer Research.

[21]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[22]  T. Conrads,et al.  Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. , 2015, Gynecologic oncology.

[23]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[24]  Sheena M. Scroggins,et al.  Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas , 2013, Clinical Cancer Research.

[25]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[26]  E. Fishman,et al.  Recent progress in pancreatic cancer , 2013, CA: a cancer journal for clinicians.

[27]  G. Rigakos,et al.  BRCAness: finding the Achilles heel in ovarian cancer. , 2012, The oncologist.

[28]  J. Minna,et al.  Targeted Therapies for Lung Cancer: Clinical Experience and Novel Agents , 2011, Cancer journal.

[29]  M. Dyer,et al.  The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. , 2010, Blood.

[30]  J. Bartek,et al.  The DNA-damage response in human biology and disease , 2009, Nature.